- New Zealand
- /
- Medical Equipment
- /
- NZSE:TRU
TruScreen Group Full Year 2025 Earnings: NZ$0.004 loss per share (vs NZ$0.005 loss in FY 2024)
TruScreen Group (NZSE:TRU) Full Year 2025 Results
Key Financial Results
- Revenue: NZ$2.11m (down 19% from FY 2024).
- Net loss: NZ$2.24m (loss widened by 9.4% from FY 2024).
- NZ$0.004 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period

TruScreen Group shares are up 3.4% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 4 warning signs for TruScreen Group (2 are significant) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if TruScreen Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NZSE:TRU
TruScreen Group
Develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, the Middle East/North Africa, and internationally.
Adequate balance sheet slight.
Market Insights
Community Narratives

